Yourgene Health Plc (VILGF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Yourgene Health Plc (VILGF) trades at $0.00. Yourgene Health Plc is a molecular diagnostics company focused on developing and commercializing gene analysis techniques. Market cap: $20.67M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for VILGF: VILGF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VILGF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VILGF: 1/1 perspectives are bearish.
How is this calculated? →Yourgene Health Plc (VILGF) Healthcare & Pipeline Overview
Yourgene Health Plc specializes in molecular diagnostics, providing prenatal screening and other gene analysis technologies. The company's key differentiators include its IONA test for Down's syndrome and its DPYD genotyping products, positioning it within the competitive medical diagnostics sector.
What Is the Investment Thesis for VILGF?
Yourgene Health Plc presents an investment case centered on its specialized position in molecular diagnostics, particularly in prenatal screening and personalized medicine. The company's IONA test and DPYD assays address critical healthcare needs. A key value driver is the increasing adoption of NIPT and personalized medicine approaches, which could expand Yourgene's market reach. Growth catalysts include potential regulatory approvals in new markets and strategic partnerships to broaden its product offerings. However, investors may want to evaluate the risks associated with operating in a highly competitive market and the challenges of securing reimbursement for diagnostic tests. The company's beta of 0.86 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
VILGF Key Highlights
- Yourgene Health Plc operates in the molecular diagnostics market, focusing on prenatal screening and personalized medicine.
- The company's key product, the IONA test, is a non-invasive prenatal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome.
- Yourgene Health offers DPYD genotyping products, aiding in predicting patient response to chemotherapy treatments.
- The company provides genomic services, sample preparation, and bioinformatics tools to clinical research organizations.
- Yourgene Health Plc has a market capitalization of $20.67M as of March 17, 2026.
Who Are VILGF's Competitors?
VILGF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.64M | 57 |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.35M | 46 |
| GRAMF TPCO Holding Corp. | $0.16 | -15.36% | $20.12M | 42 |
| HDSLF HS GovTech Solutions Inc. | $0.39 | -0.39% | $21.13M | 46 |
| KMSTF Kadimastem Ltd | $3.21 | -3.02% | $9.50M | 44 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VILGF's Key Strengths?
- Specialized expertise in prenatal screening and DPYD testing.
- Proprietary IONA test for non-invasive prenatal testing.
- Established presence in the UK and European markets.
- Offers a range of genomic services and bioinformatics tools.
What Are VILGF's Weaknesses?
- Limited geographic diversification.
- Reliance on a relatively small number of key products.
- Competition from larger, more established players.
- OTC listing may limit access to capital.
What Could Drive VILGF Stock Higher?
- Potential regulatory approvals for new diagnostic tests in key markets.
- Increasing adoption of NIPT and personalized medicine.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
What Are the Key Risks for VILGF?
- Negative return on equity (-5.8%) — the business is not currently generating profit on shareholder capital.
- Intense competition in the molecular diagnostics market.
- Regulatory changes and reimbursement challenges.
- Technological advancements that could render existing products obsolete.
- Economic downturns that could reduce healthcare spending.
- Risks associated with operating on the OTC market.
What Are the Growth Opportunities for VILGF?
- Expansion of NIPT Market: The non-invasive prenatal testing (NIPT) market is experiencing significant growth, driven by increased awareness and acceptance of NIPT as a safe and accurate screening method. Yourgene Health's IONA test is well-positioned to capitalize on this trend. The global NIPT market is projected to reach billions of dollars by 2030, offering a substantial opportunity for Yourgene to increase its market share through strategic partnerships and geographic expansion.
- Personalized Medicine and DPYD Testing: The growing emphasis on personalized medicine is creating opportunities for Yourgene's DPYD genotyping products. DPYD testing helps predict a patient's response to chemotherapy treatments, enabling clinicians to tailor treatment plans and improve patient outcomes. As personalized medicine becomes more prevalent, the demand for DPYD testing is expected to rise, providing a growth avenue for Yourgene.
- Geographic Expansion: Yourgene Health has the opportunity to expand its geographic reach beyond its current markets in the UK, Europe, and internationally. Entering new markets, particularly in Asia-Pacific and North America, could significantly increase the company's revenue and market presence. This expansion could be achieved through partnerships, acquisitions, or direct investment in new regions.
- Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other companies in the healthcare and diagnostics industries can accelerate Yourgene's growth. Collaborations can provide access to new technologies, markets, and distribution channels. For example, partnering with a pharmaceutical company to develop companion diagnostics for a new drug could create a significant revenue stream for Yourgene.
- New Product Development: Investing in research and development to create new diagnostic products and services is essential for Yourgene's long-term growth. Developing innovative tests for other genetic disorders or expanding into new areas of molecular diagnostics can diversify the company's product portfolio and reduce its reliance on existing products. This could involve developing tests for cancer, cardiovascular disease, or other prevalent health conditions.
What Opportunities Does VILGF Have?
- Expansion into new geographic markets, particularly in Asia-Pacific and North America.
- Development of new diagnostic tests for other genetic disorders.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Increasing adoption of personalized medicine and NIPT.
What Threats Does VILGF Face?
- Intense competition in the molecular diagnostics market.
- Regulatory changes and reimbursement challenges.
- Technological advancements that could render existing products obsolete.
- Economic downturns that could reduce healthcare spending.
What Are VILGF's Competitive Advantages?
- Specialized expertise in molecular diagnostics.
- Proprietary technologies, such as the IONA test.
- Established relationships with healthcare providers and research institutions.
- Regulatory approvals for key diagnostic products.
What Does VILGF Do?
Yourgene Health Plc, established in 2000 and headquartered in Manchester, UK, is a molecular diagnostics company focused on researching, developing, and commercializing gene analysis techniques. Originally named Premaitha Health PLC, the company rebranded in November 2018 to Yourgene Health Plc. The company's core business revolves around in vitro diagnostic products, including the IONA test, a non-invasive prenatal test (NIPT) designed to screen for Down's syndrome, Edwards' syndrome, and Patau's Syndrome in pregnant women. Yourgene also offers Cystic Fibrosis Screening tests, Rapid Aneuploidy Analysis for confirmatory diagnostics after amniocentesis, and Recurrent Pregnancy Loss assays. In addition to prenatal screening, Yourgene Health provides DPYD genotyping products, the Ranger technology platform for sample size selection and enrichment, and the Elucigene DPYD assay to predict a patient's response to chemotherapy. The company also offers Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for COVID-19 testing. Yourgene extends its services to genomic services, sample preparation and analysis tools, and bioinformatics and software products. These services include extraction for DNA, RNA/miRNA, and nucleons; quantification; genotyping; gene expression; methylation; and microarray services for clinical research organizations. Yourgene Health operates primarily in the United Kingdom, Europe, and internationally, serving clinical research organizations and healthcare providers.
What Products and Services Does VILGF Offer?
- Develops and commercializes gene analysis techniques.
- Offers non-invasive prenatal testing (NIPT) for Down's syndrome and other genetic disorders.
- Provides cystic fibrosis screening tests.
- Offers rapid aneuploidy analysis for confirmatory diagnostics.
- Provides recurrent pregnancy loss assays.
- Develops DPYD genotyping products to predict patient response to chemotherapy.
- Offers genomic services and bioinformatics tools to clinical research organizations.
How Does VILGF Make Money?
- Develops and sells in vitro diagnostic products.
- Provides genomic services to clinical research organizations.
- Generates revenue from sales of diagnostic tests and services.
- Partners with healthcare providers and research institutions to expand market reach.
What Industry Does VILGF Operate In?
Yourgene Health Plc operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for personalized medicine. The market for molecular diagnostics is projected to grow, driven by advances in genomics and proteomics. Competition is intense, with major players like ATHJF (Agile Therapeutics Inc), BFFTF (BioFiltration Systems Inc), GRAMF (Graminex LLC), HDSLF (Hudson Technologies Inc), and KMSTF (Komo Stores Inc) vying for market share. Yourgene's focus on prenatal screening and DPYD testing positions it within specific niches of this broader market.
Who Are VILGF's Key Customers?
- Pregnant women undergoing prenatal screening.
- Healthcare providers offering prenatal care.
- Clinical research organizations conducting genetic research.
- Patients undergoing chemotherapy treatment.
Company Profile
Yourgene Health Plc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Manchester, GB. The company is led by CEO Lyn Dafydd Rees. VILGF has traded publicly since 2013.
Yourgene Health Plc (VILGF) Valuation Context
Valued at $20.67M, VILGF is classified as a micro-cap stock.
ROE -6%Key Financial Metrics
Return on equity for Yourgene Health Plc stands at -5.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.77 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -51.6%, the inverse of the P/E and a quick read on earnings relative to price.
VILGF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized expertise in prenatal screening and DPYD testing.
- Proprietary IONA test for non-invasive prenatal testing.
- Established presence in the UK and European markets.
- Offers a range of genomic services and bioinformatics tools.
Bear Case
- Limited geographic diversification.
- Reliance on a relatively small number of key products.
- Competition from larger, more established players.
- OTC listing may limit access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
VILGF Latest News
No recent news available for VILGF.
VILGF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VILGF.
Price Targets
Wall Street price target analysis for VILGF.
VILGF MoonshotScore
What does this score mean?
The MoonshotScore rates VILGF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Lyn Dafydd Rees
CEO
Lyn Dafydd Rees serves as the CEO of Yourgene Health Plc, bringing extensive experience in the healthcare and diagnostics industries. His background includes leadership roles in various biotechnology and pharmaceutical companies, focusing on strategic development, commercialization, and market access. He has a proven track record of driving growth and innovation in the healthcare sector. His expertise spans across molecular diagnostics, genomics, and personalized medicine, making him well-suited to lead Yourgene Health.
Track Record: Under Lyn Dafydd Rees' leadership, Yourgene Health Plc has focused on expanding its product portfolio and geographic reach. Key achievements include the commercialization of new diagnostic tests and the establishment of strategic partnerships. He has overseen the company's efforts to navigate regulatory approvals and secure reimbursement for its products. His strategic decisions have aimed to position Yourgene Health as a leader in the molecular diagnostics market.
VILGF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Yourgene Health Plc may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial information available and may be subject to greater risks. Investing in OTC Other stocks involves a higher degree of speculation compared to stocks listed on major exchanges like the NYSE or NASDAQ, due to less stringent listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Greater price volatility.
- Potential for fraud or manipulation.
- Limited regulatory oversight.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any legal or regulatory issues.
- Established presence in the molecular diagnostics market.
- Proprietary technologies and diagnostic products.
- Partnerships with healthcare providers and research institutions.
- CEO with experience in the healthcare industry.
- Company incorporated in 2000.
Common Questions About VILGF (Healthcare)
What does Yourgene Health Plc do?
Yourgene Health Plc is a molecular diagnostics company that develops and commercializes gene analysis techniques for prenatal screening and other applications. The company's core products include the IONA test, a non-invasive prenatal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome, as well as DPYD genotyping products to predict patient response to chemotherapy. Yourgene also provides genomic services and bioinformatics tools to clinical research organizations, positioning itself as a key player in the molecular diagnostics market.
What do analysts say about VILGF stock?
As of March 17, 2026, there is no readily available analyst consensus on VILGF stock due to its OTC listing and smaller market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics may be difficult to obtain due to limited financial disclosure. Growth considerations include the increasing adoption of NIPT and personalized medicine.
What are the main risks for VILGF?
The main risks for Yourgene Health Plc include intense competition in the molecular diagnostics market, regulatory changes and reimbursement challenges, and technological advancements that could render existing products obsolete. Additionally, the company faces risks associated with operating on the OTC market, such as limited liquidity and greater price volatility. Economic downturns could also reduce healthcare spending, impacting the demand for Yourgene's products and services. Investors should carefully consider these risks before investing in VILGF.
What are the key factors to evaluate for VILGF?
Evaluate VILGF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does VILGF data refresh on this page?
VILGF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven VILGF's recent stock price performance?
Yourgene Health Plc (VILGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in prenatal screening and DPYD testing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VILGF overvalued or undervalued right now?
Valuing Yourgene Health Plc (VILGF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying VILGF?
Before investing in Yourgene Health Plc (VILGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available due to OTC listing.
- Analyst coverage may be limited.